Literature DB >> 25433437

Diabetes medications and bone.

Andrew Grey1.   

Abstract

Type 2 diabetes mellitus (T2DM) is a common chronic disease that may be associated with an increased risk of fracture. Evidence that thiazolidinediones (TZDs) increase fracture risk in women with T2DM has focused attention on the skeletal effects of treatments for diabetes. Only scant, low-quality evidence is available for non-TZD diabetes medications and bone health, but it suggests that there are no clinically important effects.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25433437     DOI： 10.1007/s11914-014-0250-z

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


  61 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 2.  Type 2 diabetes and bone.

Authors:  William D Leslie; Mishaela R Rubin; Ann V Schwartz; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-09-28       Impact factor: 6.741

3.  Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

Authors:  Mathijs C Bunck; Marieke Poelma; E Marelise Eekhoff; Anja Schweizer; Robert J Heine; Giel Nijpels; James E Foley; Michaela Diamant
Journal:  J Diabetes       Date:  2012-06       Impact factor: 4.006

4.  Fracture risk in diabetic elderly men: the MrOS study.

Authors:  Nicola Napoli; Elsa S Strotmeyer; Kristine E Ensrud; Deborah E Sellmeyer; Douglas C Bauer; Andrew R Hoffman; Thuy-Tien L Dam; Elizabeth Barrett-Connor; Lisa Palermo; Eric S Orwoll; Steven R Cummings; Dennis M Black; Ann V Schwartz
Journal:  Diabetologia       Date:  2014-06-09       Impact factor: 10.122

5.  Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats.

Authors:  Justyna Fronczek-Sokół; Maria Pytlik
Journal:  Pharmacol Rep       Date:  2014-04-13       Impact factor: 3.024

6.  Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Authors:  J Bolinder; Ö Ljunggren; L Johansson; J Wilding; A M Langkilde; C D Sjöström; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

7.  Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study.

Authors:  M Salai; D Somjen; R Gigi; O Yakobson; S Katzburg; O Dolkart
Journal:  Bone Joint J       Date:  2013-11       Impact factor: 5.082

8.  Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass.

Authors:  Ding Xie; Qing Zhong; Ke-Hong Ding; Hua Cheng; Sandra Williams; Daniel Correa; Wendy B Bollag; Roni J Bollag; Karl Insogna; Nancy Troiano; Chistiane Coady; Mark Hamrick; Carlos M Isales
Journal:  Bone       Date:  2007-01-20       Impact factor: 4.398

9.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

10.  Osteoblast differentiation is functionally associated with decreased AMP kinase activity.

Authors:  Takayuki Kasai; Kenjiro Bandow; Hiraku Suzuki; Norika Chiba; Kyoko Kakimoto; Tomokazu Ohnishi; Shin-ichiro Kawamoto; Eiichi Nagaoka; Tetsuya Matsuguchi
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384
View more
  2 in total

1.  Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care.

Authors:  S Pscherer; K Kostev; F W Dippel; W Rathmann
Journal:  Diabetes Metab Syndr Obes       Date:  2016-02-19       Impact factor: 3.168

2.  VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity.

Authors:  Belen Palomares; Francisco Ruiz-Pino; Carmen Navarrete; Inmaculada Velasco; Miguel A Sánchez-Garrido; Carla Jimenez-Jimenez; Carolina Pavicic; Maria J Vazquez; Giovanni Appendino; M Luz Bellido; Marco A Calzado; Manuel Tena-Sempere; Eduardo Muñoz
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.